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ABSTRACT
Objectives To determine the effectiveness of
corticosteroidsinreducingrespiratorydisordersininfants
born at 34-36 weeks’ gestation.
Design Randomised triple blind clinical trial.
Setting A large tertiary teaching hospital in northeast of
Brazil.
Participants Women at 34-36 weeks of pregnancy at risk
of imminent premature delivery.
Interventions Betamethasone 12 mg or placebo
intramuscularly for two consecutive days.
Main outcomes measures Primary outcome was the
incidence of respiratory disorders (respiratory distress
syndrome and transient tachypnoea of the newborn).
Secondary outcomes included the need for ventilatory
support, neonatal morbidity, and duration of stay in
hospital.
Results320womenwererandomised,163 ofwhom were
assigned to the treatment group and 157 to the controls.
Finalanalysisincluded143and130infants,respectively.
The rate of respiratory distress syndrome was low (two
(1.4%) in the corticosteroid group; one (0.8%) in the
placebo group; P=0.54), while the rate of transient
tachypnoea was high in both groups (34 (24%) v 29
(22%); P=0.77). There was no reduction in the risk of
respiratory morbidity with corticosteroid use even after
adjustment for subgroups of gestational age (34-34
+6
weeks,35-35
+6weeks,and ≥36weeks).Theadjustedrisk
of respiratory morbidity was 1.12 (95% confidence
interval 0.74 to 1.70). The need for ventilatory support
was around 20% in both groups. There was no difference
inneonatalmorbidity(88(62%)v93(72%);P=0.08)orin
the duration of stay in hospital between the two groups
(5.12v5.22days;P=0.87).Phototherapyforjaundicewas
required less often in babies whose mothers received
corticosteroids (risk ratio 0.63, 0.44 to 0.91).
Conclusions Antenatal treatment with corticosteroids at
34-36 weeks of pregnancy does not reduce the incidence
of respiratory disorders in newborn infants.
Trial registration Clinical Trials NCT00675246.
INTRODUCTION
Though late preterm infants were previously thought
to be as physiologically and metabolically mature as
term infants, we now know they are at a higher risk of
morbidity and mortality.
1-4 As late preterm infants
represent the majority of premature infants, they
have a considerable impact on the healthcare system
compared with full term infants.
5-8
Respiratory disorders are often associated with late
prematurityandare morecommoninthaninfull term
infants (29% v 4%
3). There is a greater risk of the infant
requiringoxygenandventilatorysupportandofbeing
admitted to intensive care.
910 The most common
respiratory disorders are transient tachypnoea of the
newborn, respiratory distress syndrome, pneumonia,
and pulmonary hypertension.
3
Prevention of these disorders has been a concern,
andvariousinvestigatorshavesuggestedthatantenatal
treatment with corticosteroids could accelerate lung
maturationinlatepreterminfants.
11-13Thoughtheben-
eficial effects of corticosteroids before 34 weeks of
pregnancy have been well established,
1415 we do not
know whether these effects extend beyond the
34th week.
Only limited evidenceon thisissueis availablefrom
two studies
1617 included in the Cochrane review that
addressed the outcomes of babies born at 33 and 34
+6
weeks’ gestation.
15 The review concluded that there
was a significant reduction in respiratory distress syn-
drome in babies born between 33 and 34
+6 weeks’
gestation but no significant reduction in babies born
between 35 and 36
+6 weeks’ gestation (relative risk
0.61, 95% confidence interval 0.11 to 3.26, one study,
189 cases).
15
We carried out a randomised controlled trial to
determine the effectiveness of antenatal treatment
with corticosteroids at 34-36 weeks of pregnancy in
reducing the incidence of neonatal respiratory
disorders.
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Study design
We carried out a randomised, triple blind, placebo
controlled clinical trial between April 2008 and June
2010 at the Instituto de Medicina Integral Prof Fer-
nandoFigueira(IMIP),Recife,alargetertiaryteaching
hospital in the northeast of Brazil.
Study population
The sample size was calculated with open source soft-
ware (Openepi version 2.3, Atlanta, GA), with an
assumed 28.9% rate of respiratory disorders in late pre-
terminfants,
3anαerrorof5%,and80%powertodetect
a reduction of 50% in the rate of respiratory disorders
with the use of corticosteroids.
15 This resulted in a
required sample size of 266 (133 in each group), which
we increased to 320 to cater for losses and exclusions.
Pregnant women receiving care at the institute were
included if they were at 34-36
+6 weeks’ gestation and
were at risk of imminent premature delivery (either
spontaneously or if early delivery was recommended
as a result of problems with the mother or fetus, or
both) at the time of admission to hospital. Gestational
age was defined according to the date of the woman’s
last menstrual period, if known and reliable, or by
ultrasonography before 20 weeks of pregnancy. Rea-
sons for exclusion from the study included multiple
pregnancy, major congenital malformations, haemor-
rhagic syndromes with active bleeding, clinical evi-
dence of chorioamnionitis, previous use of
corticosteroids, or need for immediate resolution of
pregnancy for maternal or fetal reasons. Women who
were discharged from hospital while still pregnant and
who went on to deliver elsewhere were excluded from
the study after randomisation.
Randomisation and follow-up
A statistician who was not involved in the study pre-
paredatableofrandomnumbersinasingleblock(ran-
domallocationsoftware,version1.0),with163women
randomised to receive betamethasone and 157 to pla-
cebo. The hospital pharmacy prepared 320 sealed
cardboard boxes, each containing four ampoules of
betamethasone or placebo, identical in appearance,
volume, and colour, and numbered in accordance
with the table of random numbers. Each ampoule of
betamethasone contained 6 mg (3 mg acetate and
3.9 mg disodium phosphate) and was prepared by the
Laboratório Mantecorp (Rio de Janeiro, Brazil). The
placebo ampoules contained a similar volume of
0.9% saline solution and were prepared for this trial
by the pharmacy department of the Clinics Hospital,
University of San Paulo.
Only the pharmacist responsible for preparing the
boxes was aware of their contents. The investigators,
the physicians who cared for the women, the statisti-
cian, and the women themselves were unaware of the
contents;thisinformationwasdisclosedonlyafterdata
analysis was complete.
The physicians in charge of the obstetrics department
identified potentially eligible women, who were then
approached by the investigators. Only after they had
signed an informed consent form did those women
agreeing to participate in the study receive the sealed
cardboard box corresponding to their randomisation
group. Two ampoules were applied intramuscularly,
with two more being administered 24 hours later. The
studyinvestigatorstooknopartintheprepartumorpost-
partum management of the women or in neonatal man-
agement. Women in premature labour underwent
tocolysiswithnifedipine,inaccordancewiththehospital
routine practice, in an attempt to postpone delivery and
allow the full course of medication to be administered.
The investigators and the neonatologist who fol-
lowed up the infants prospectively collected data on
the pregnant women and their newborns on a standar-
dised form.
If the woman delivered before she received the sec-
onddoseofthemedication,shewasanalysedaspartof
thegrouptowhichshehadbeenrandomised(intention
to treat analysis). If the woman completed the sched-
uled regimen but was discharged while still pregnant
and went on to deliver in another hospital, she was
considered a post-randomisation loss to follow-up.
Outcomes evaluated
The primary outcomes were the occurrence of neona-
talrespiratorydisorders:respiratorydistresssyndrome
ortransienttachypnoeaofthenewborn,definedbythe
presence of respiratory distress for more than two
hours after birth and characterised by tachypnoea,
expiratory grunting, chest wall retractions, flaring of
the nostrils, cyanosis, and a growing need for
oxygen.
3 We used radiological criteria to differentiate
between the two disorders used: diffuse reticulogranu-
larinfiltrateinrespiratorydistresssyndromeandthick-
ening of the bronchovascular bundle, pulmonary
Table 1 |Baseline characteristics of women at 34-36 weeks of pregnancy at risk of imminent
premature delivery according to antenatal treatment with corticosteroids or placebo. Figures
are numbers (percentages) unless stated otherwise
Variable Corticosteroid (n=143) Placebo (n=130)
Mean (SD) age (years) 23.3 (6.1) 22.9 (5.5)
Median (IQR) No of pregnancies 1 (1-3) 1.5 (1-3)
Primigravidas 72 (50) 65 (50)
Median (IQR) No of deliveries 0 (0-1) 0 (0-1)
Nulliparas 78 (55) 69 (53)
Gestational age at admission (weeks):
Range 34-36 34-36
Mean (SD) 35.0 (0.7) 35.0 (0.7)
History of prematurity 20 (14) 12 (9)
Associated conditions:
Hypertension 33 (23) 36 (28)
Premature rupture of membranes 54 (38) 54 (42)
Premature labour 97 (68) 86 (66)
Diabetes 3 (2) 2 (2)
Fetal growth restriction 1 (0.7) 2 (2)
Oligohydramnios 15 (11) 5 (4)
Others 20 (14) 12 (9)
Received tocolytics (nifedipine) 88 (62) 79 (61)
IQR=interquartile range.
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lobar fissures in transient tachypnoea of the
newborn.
18
The secondary outcomes included type of delivery
and neonatal outcomes: gestational age at birth, birth
weight, Apgar scores at one and five minutes; treat-
ment with exogenous surfactant, ventilatory support
(presence, duration, and type; invasive or non-inva-
sive), and admission to intensive care; neonatal hypo-
glycaemia, neonatal jaundice (presence of and
requirement for phototherapy), persistence of ductus
arteriosus, neonatal sepsis, and neonatal morbidity
(any one of the respiratory complications or any
other morbidities); and duration of stay in hospital
and death.
Statistical analysis
Statistical analysis was performed with EpiInfo soft-
ware version 3.5.1 (Centers for Disease Control and
Prevention, Atlanta, GA), under the intention to treat
principle. The statistician and the investigators
remainedblindtothe treatmentgroupsuntilthetables
had been prepared and the analysis concluded.
Thebaselinecharacteristicsoftheparticipantsineach
group were compared with Student’s t test for continu-
ousvariableswithnormaldistributionandMann-Whit-
ney U test for discrete and ordinal variables or those
with non-normal distribution. Categorical variables
were compared with Pearson’s χ
2 test or Fisher’se x a c t
test,as appropriate.P values for alltestswere two tailed
and the level of significance was defined at 5%. The
sametestswereusedtodeterminetheeffectsofcorticos-
teroid treatment on perinatal outcomes.
To compare respiratory and other neonatal compli-
cations in accordance with whether corticosteroid or
placebo was used, we calculated risk ratios as a mea-
sureofrelativerisk,togetherwiththeir95%confidence
intervals. We carried out a Mantel-Haenszel stratified
analysis to determine the risk of these complications
after adjustment for gestational age. The number
needed to treat was calculated with its 95% confidence
interval for the outcomes in which we found a benefi-
cial effect of corticosteroid treatment.
RESULTS
Atotalof352womenfulfilledtheadmissioncriteriafor
the study.Of these, 320 agreed to participateand were
randomised to receive betamethasone (n=163) or pla-
cebo (n=157). Forty three women were discharged
from hospital during pregnancy and were lost to fol-
low-up(19and24,respectively).Twootherexclusions
occurred after randomisation in the placebo group:
one because a twin pregnancy was detected only after
randomisation and one because the pregnancy was
found to have already reached term. Therefore, 144
women remained in the corticosteroid group and 131
intheplacebogroup,with13%oflossesafterrandomi-
sation (43 cases). As one stillbirth occurred in each
group, we analysed 143 babies in the intervention
group and 130 in the control group (figure).
There were no significant differences between
groups in most baseline characteristics (table 1). In
both groups 78% of the women received the full regi-
men of two doses (111 in intervention group, 101 in
placebogroup),andtherewasnosignificantdifference
between the groups in this respect. The interval
between administration of the last dose and delivery
was a median of two days in both groups (interquartile
range 1-4; P=0.49). No local or systemic side effects
occurred, and there were no unexpected effects or
adverse reactions to corticosteroid treatment (data
not shown in tables). Perinatal outcomes were similar
(table 2).
In both groups there were low rates of respiratory
distress syndrome (two cases (1.4%) in the corticoster-
oid group and one case (0.8%) in the placebo group;
P=0.54) and high rates of transient tachypnoea of the
newborn (34 cases (24%) v 29 cases (22%); P=0.77)
(table 3). Treatment with corticosteroids failed to
reduce the risk of any respiratory morbidity (risk
ratio 1.09, 95% confidence interval 0.72 to 1.66).
Only one baby in the corticosteroid group required
exogenous surfactant. Necessity for ventilatory sup-
port was also similar, at around 20% in both groups
(28 cases (20%) in the corticosteroid group and 24
cases(19%)intheplacebogroup).Therewasnodiffer-
ence in the type of ventilatory support used, and the
meandurationofventilationwas2.2daysintheinfants
in the corticosteroid group and 2.8 days in the placebo
group (P=0.65) (table 3).
We performed a stratified analysis to detect any dif-
ferences in the effect of corticosteroid by gestational
age(34,35,and36weeksormore).Therateofrespira-
tory disorders was 50% (15/30), 25% (28/111), and
17% (23/132), respectively, and there were no signifi-
cant differences between the groups. The corticoster-
oid had no effect in reducing respiratory morbidity at
34, 35, and 36 or more weeks, and the risk of respira-
tory disorders for the use of corticosteroid adjusted for
gestational age was 1.12 (0.74 to 1.70) (table 4).
Table 2 |Perinatal outcomes in infants born at 34-36 weeks of pregnancy at risk of imminent
premature delivery according to antenatal treatment with corticosteroids or placebo
Variable
Corticoster-
oid (n=143)
Placebo
(n=130)
Relative risk
(95% CI) P value
No (%) of vaginal deliveries 98 (69) 90 (69) 0.99 (0.84 to 1.16) 0.90
Mean (SD) gestation at delivery (weeks) 35.6 (1.17) 35.5 (1.08) — 0.71
No (%) <37 weeks’ gestation 127 (89) 119 (92) 0.97 (0.90 to 1.05) 0.45
Mean (SD) birth weight (g) 2640 (445) 2627 (452) — 0.80
No (%) <2500 g 49 (34) 51 (39) 0.87 (0.64 to 1.19) 0.40
No (%) small for gestational age 35 (25) 29 (22) 1.10 (0.71 to 1.69) 0.67
Apgar score:
Median (IQR) score at one minute 8 (8-9) 8 (8-9) — 0.20*
No (%) <7 at one minute 19 (13) 19 (15) 0.91 (0.50 to 1.64) 0.75
Median (IQR) score at five minutes 9 (9-10) 9 (9-10) — 0.77*
No (%) <7 at five minutes 1 (1) 2 (2) 0.45 (0.04 to 4.95) 0.46†
IQR=interquartile range.
*Mann-Whitney test.
†Fisher’s exact test.
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mia (15 (11%) v 9 (7%)), and sepsis (6 (4%) v 9 (7%))
were similar in the two groups. Nevertheless, the rate
ofjaundicerequiringphototherapywaslowerinbabies
whose mothers had received corticosteroids (34 (24%)
v 49 (38%); P=0.01), resulting in a 47% lower risk of
requiring phototherapy and a number needed to treat
of 7 (4 to 33). There was no difference in the outcomes
ofneonatalmorbidity(88(61.5%)v93(71.5%)),admis-
sion to intensive care (47 (33%) v 43 (33%)), or rate of
neonatal death (two (2%) in the placebo group). The
deaths in the placebo group were associated with
severe perinatal asphyxia. The duration of stay in hos-
pital was also similar in the two groups (5.1 v 5.2 days)
(table 5).
DISCUSSION
Our randomised controlled trial shows that antenatal
treatment with corticosteroids in women at
34-36 weeks of pregnancy at risk of imminent prema-
ture delivery is ineffective in reducing the occurrence
of respiratory disorders in the babies and fails to exert
any effect on the incidence of various other complica-
tionsoflateprematurity,withtheexceptionofjaundice
requiringphototherapy.Ourstudyshowsthatlatepre-
terminfantsdevelophighratesoftransienttachypnoea
(around 23%) and neonatal morbidity, confirming
observations reported over the past decade from a
range of different settings.
2-4
Antenatal treatment with corticosteroids has been
used to accelerate lung maturation for more than
three decades, and its effectiveness and safety is well
established for pregnancies of up to 34 weeks.
14-17 A
possible extension of the benefits of corticosteroids
beyondthisgestationalage,however,hasonlyrecently
been more widely considered.
11-13
Comparison with other studies
In two published meta-analyses, gestational age sub-
groups showed insufficient evidence to either recom-
mendordiscouragetheuseofcorticosteroidsafter34
+6
weeks of pregnancy.
1415 Although some studies have
suggested a reduction in the risk of respiratory disor-
ders, both the number of infants of this gestational age
and the number of respiratory events were low, with
insufficient power to detect any significant difference.
In contrast, another meta-analysis published in 1995
showed that one would need to treat 94 pregnant
women beyond 34 weeks’ gestation to prevent one
case of respiratory distress syndrome.
19
The ASTECS study evaluated the effectiveness of
antenatalcorticosteroidsin 998 womenwhowere can-
didates for full term elective caesarean section and
reported a significant reduction of around 54% in
admissions to neonatal intensive care for respiratory
disorders.
20Nevertheless,thatstudyhadvariousmeth-
odologicallimitations:itwasnotblindedandtherewas
no placebo group, the intervention group being com-
pared with treatment referred to as “usual.” In addi-
tion, despite a reduction in the rate of admission to
neonatal intensive care, they found no reduction in
the objective measures of respiratory morbidity, and,
most importantly, their population of women with
elective caesarean section before 40 weeks is different
from the women in our study. The ASTECS study
excluded women in labour and those with hyperten-
sive syndromes and did not mention the state of the
amnioticmembranes,whereasinourstudyonlatepre-
maturedelivery,prematureruptureofmembranesand
hypertensive syndromes were the most common con-
ditions.
Did not agree to participate (n=32)
Agreed to participate (n=320)
Women at risk of imminent premature delivery at 34-36 weeks’ gestation (n=1103)
Eligible women (n=352)
Randomisation (n=320)
Losses and exclusions (n=20):
  Discharged while still pregnant (n=19)
  Stillbirth (n=1)
Losses and exclusions (n=20):
  Discharged while still pregnant (n=24)
  Twin pregnancy* (n=1)
  Full term pregnancy (n=1)
  Stillbirth (n=1)
Ineligible and excluded (n=751):
  Indication of immediate interruption of pregnancy (n=270)
  Uncertain gestational age (n=219)
  Previous use of corticosteroids (n=153)
  Fetal malformation (n=51)
  Multiple pregnancy (n=43)
  Third trimester haemorrage (n=15)
Placebo group (n=157)
Received placebo IM
for 2 consecutive days
Corticosteroid group (n=163)
Received betamethasone
12 mg IM for 2 consecutive days
Infants analysed (n=130) Infants analysed (n=143)
Procedures for selection and follow-up of participants. *Confirmed only after randomisation.
IM=intramuscular
Table 3 |Respiratory complications in infants born to women at 34-36 weeks of pregnancy at
risk of imminent premature delivery according to antenatal treatment with corticosteroids or
placebo. Figures are numbers (percentages) unless stated otherwise
Variable
Corticoster-
oid (n=143)
Placebo
(n=130)
Risk ratio
(95% CI) P value
Respiratory morbidity 36 (25) 30 (23) 1.09 (0.72 to 1.66) 0.69
Type of respiratory morbidity:
Respiratory distress syndrome 2 (1) 1 (1) 1.82 (0.17 to 19.8) 0.54*
Transient tachypnoea 34 (24) 29 (22) 1.07 (0.69 to 1.65) 0.77
Use of surfactant 1 (1) 0 —† 0.52*
Ventilatory support:
Any 28 (20) 24 (19) 1.06 (0.65 to 1.73) 0.81
Invasive (mechanical ventilation) 2 (1) 1 (1) 1.82 (0.17 to 19.82) 0.54*
Non-invasive 26 (18) 23 (18) 1.03 (0.62 to 1.71) 0.92
>1 day of ventilation 10 (36) 11 (46) 0.78 (0.40 to1.51) 0.46
Mean (SD) duration (days) 2.2 (2.8) 2.8 (5.9) — 0.65
*Fisher’s exact test.
†Not estimated.
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full term pregnancies suggests that further studies are
required to investigate its effect on neonatal
outcomes,
21 there are safer and more effective mea-
sures of preventing respiratory disorders, such as
avoiding unnecessary caesarean sections and delaying
elective caesarean sections, whenever indicated, until
after 39 weeks of pregnancy
2223
Antenatal administration accelerates the effect of
endogenous corticosteroids and induces the produc-
tion of all the known components of the surfactant
system.
1324 As respiratorydistress syndrome is charac-
terised by a qualitative and quantitative deficiency of
pulmonary surfactants, infants born before 34 weeks’
gestation, in whom the incidence of this syndrome is
higher, benefit from the administration of antenatal
corticosteroids.
1415 Respiratory distress syndrome,
however,ismuchlesscommoninlatepreterminfants,
in whom the principal respiratory disorder is transient
tachypnoea. This develops from a delay in the absorp-
tionoflungfluidorinitsinadequateclearancefromthe
upper airways, resulting in more fluid in the lungs and
reducedpulmonarycomplacency,leadingtothe onset
of symptoms.
25 Antenatal corticosteroids could facili-
tate clearance of fetal lung fluid by activating the
epithelial sodium channels and increasing ion
transport,
2026thoughthismechanismhasnotbeencon-
firmed by other studies.
Another finding that merits debate concerns the
reduction in the risk of neonatal jaundice requiring
phototherapy, which we found was the only beneficial
effectofcorticosteroids.Otherclinicaltrialshadalready
shown this effect in premature infants born before
34weeks’gestation,
27anditispossiblethatlivermatura-
tion could also be accelerated with corticosteroids.
Nevertheless, the actual mechanisms underlying this
effect and their implication in reducing neonatal mor-
bidity in late preterm infants remain to be clarified.
Limitations of study
In our study, 43 (13%) pregnant women were dis-
charged after randomisation, went on to give birth in
another hospital, and were lost to follow-up. Most of
these women were discharged after 35 weeks of preg-
nancy and some could have reached full term; there-
fore, it is unlikely that significant rates of respiratory
disorders or other neonatal morbidities could have
been affected by the administration of corticosteroids.
We believe that these losses, albeit a limitation of the
study, had no effect on our conclusions.
Powering a study to detect a 50% reduction always
runs the risk of missing smaller but clinically important
reductions in the primary outcome. We do not believe
that this has occurred because rates of respiratory mor-
bidity, especially transient tachypnoea, were similar
between groups. The real impact of steroids on the rates
of respiratory distress syndrome remains to be estab-
lished as these are quite low and our study was not pow-
ered to detect real differences between the groups.
Conclusions and policy implications
In the medical care of highrisk pregnancies,the domi-
nant concept, up until recently, suggested that there
wouldbelittleneedforfurtherconcernregardingneo-
natal outcomes after 34 weeks of pregnancy. Recent
evidence has not supported this. Despite having low
mortality rates, late preterm infants have been shown
to be affected by clinically important morbidity, and a
review of the evidence in support of current clinical
practice is warranted. Unfortunately, our study sug-
gests that antenatal treatment with corticosteroid does
not result in significant reduction in neonatal respira-
tory morbidity.
Although the “safe” limit for interrupting a high risk
pregnancyremainstobeestablished,allowingthebaby
to remain in the uterus as long as maternal conditions
and fetal wellbeing permit seems to be the key to pre-
venting the complications of prematurity. We do not
recommend delaying delivery in women with high
risk pregnancies. What we are proposing, if we recog-
nisethehighneonatalmorbidityinlatepreterminfants,
ischangingtheparadigmofinterruptionofpregnancies
reaching 34 weeks, based on the traditional belief that
these infants are as physiologically and metabolically
Table 4 | Stratified analysis: risk of respiratory morbidity according to gestational age and
allocation to antenatal treatment with corticosteroids or placebo
Variable Respiratory morbidity Riskratio*(95%CI) P value
All gestational ages
Corticosteroid group (n=143) 36 (25) 1.09 (0.72 to 1.66)*
0.69
Placebo group (n=130) 30 (23) 1.00
34-34
+6 weeks
Corticosteroid group (n=13) 7 (54) 1.14 (0.56 to 2.33)
0.71
Placebo group (n=17) 8 (47) 1.00
35-35
+6 weeks
Corticosteroid group (n=64) 18 (28) 1.32 (0.67 to 2.60)
0.41
Placebo group (n=47) 10 (21) 1.00
≥ ≥36 weeks
Corticosteroid group (n=66) 11 (17) 0.92 (0.44 to 1.93)
0.82
Placebo group (n=66) 12 (18) 1.00
*χ
2=0.51 for differing risk ratios by stratum, P=0.77.
†Adjusted 1.12 (0.74 to 1.70).
Table 5 |Other complications and neonatal outcomes in infants born at 34-36 weeks
according to antenatal treatment with corticosteroids or placebo. Figures are numbers
(percentages) unless stated otherwise
Variable
Corticoster-
oid (n=143)
Placebo
(n=130)
Risk ratio
(95% CI) P value
Jaundice 76 (53) 73 (57) 0.94 (0.76 to 1.17) 0.57
Jaundice requiring phototherapy 34 (24) 49 (38) 0.63* (0.44 to 0.91) 0.01
Hypoglycaemia 15 (11) 9 (7) 1.50 (0.68 to 3.32) 0.31
Neonatal sepsis 6 (4) 9 (7) 0.60 (0.22 to 1.64) 0.32
Neonatal morbidity 88 (62) 93 (72) 0.86 (0.73 to 1.02) 0.08
Admission to intensive care 47 (33) 43 (33) 0.99 (0.71 to 1.39) 0.97
Neonatal death 0 2 (2) —† 0.23‡
<4 days in hospital 73 (51) 53 (41) 1.25 (0.96 to 1.63) 0.09
Mean (SD) days in hospital 5.1 (6.1) 5.2 (4.3) — 0.87
*Number needed to treat=7 (4 to 33).
†Not estimated.
‡Fisher’s exact test.
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edge about this population, we believe that expectant
management should be adopted whenever maternal
conditions and fetal wellbeing allow in an attempt to
prevent complications of prematurity.
Our results, albeit robust, could reflect the situation
adopted in this protocol of a single centre and health-
care system. Additional randomised trials should be
conducted to avoid hasty conclusions in the light of a
single study. A large randomised multicentre clinical
trial would be ideal to confirm these findings with a
sufficient number of patients to detect small or occa-
sional benefits of antenatal corticosteroids in cases of
late prematurity. Furthermore, a meta-analysis of var-
ious future randomised clinical trials could encompass
a larger number of patients and therefore strengthen
and give greater relevance to our findings. The US
National Institute of Child Health and Human Devel-
opment (NICHD) is currently recruiting a target of
2800 women into its antenatal late preterm steroids
(ALPS) trial, with the final analysis expected in 2013
(http://clinicaltrials.gov/ct2/show/NCT01222247).
Until these studies become available, current evi-
dencedoesnotjustifytheroutineuseofcorticosteroids
to prevent respiratory morbidity in late preterm
infants. Incorporating these results into the available
Cochrane review
15 would help clinicians in deciding
whether or not to prescribe steroids in women over
34 weeks’ gestation.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Antenatal treatment with corticosteroids has been used to accelerate lung maturation in
preterm infants, especially those born before 34 weeks’ gestation
The effect of corticosteroids is mediated through acceleration of endogenous corticosteroids
and increased production of all the components of the surfactant system
Preterm infants born between 34 and 36 weeks also have increased risk of respiratory
disorders, mainly transient tachypnoea
WHAT THIS STUDY ADDS
The incidence of respiratory disorders (respiratory distress syndrome and transient
tachypnoea) isnot affectedbyantenataladministrationoftwo dosesofbetamethasone after
34 weeks’ gestation
Antenatal betamethasone given after 34 weeks’ gestation reduced the risk of neonatal
jaundice requiring phototherapy, possibly because of acceleration of liver maturation
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